ZyVersa Therapeutics (ZVSA) Income Statement (2021 - 2026)
Income Statement report data from Mar 31, 2021 to Mar 31, 2026 for ZyVersa Therapeutics (ZVSA).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||||||||||||||
Research And Development | 60K (-25.00%) | 80K (-78.38%) | 370K (-9.76%) | 410K (+57.69%) | 260K (+116.67%) | 120K (-72.73%) | 440K (-38.03%) | 710K (+39.22%) | 510K (+96.15%) | 260K (-61.19%) | 670K (-45.08%) | 1.22M (+15.09%) | 1.06M (+165.00%) | 400K | - | - | - | - | - |
Selling General And Administrative | 1.25M (+165.96%) | 470K (-72.99%) | 1.74M (+6.75%) | 1.63M (-13.76%) | 1.89M (+61.54%) | 1.17M (-36.07%) | 1.83M (-10.29%) | 2.04M (-11.69%) | 2.31M (+51.97%) | 1.52M (-31.84%) | 2.23M (-43.26%) | 3.93M (+11.02%) | 3.54M (+742.86%) | 420K | - | - | - | - | - |
Operating Expenses | 1.30M (+136.36%) | 550K (-97.35%) | 21M (+917.16%) | 2.04M (-4.67%) | 2.14M (+65.89%) | 1.29M (-43.17%) | 2.27M (-17.45%) | 2.75M (-2.83%) | 2.83M (-79.68%) | 14M (+380.34%) | 2.90M (-96.64%) | 86M (+1780.83%) | 4.59M (+459.76%) | 820K | - | - | - | - | - |
Depreciation And Amortization | - | - | - | - | - | - | - | - | - | 10K | - | - | - | - | - | - | - | - | - |
Operating Income | |||||||||||||||||||
Operating Income | -1.30M (+136.36%) | -550.00K (-97.35%) | -20.75M (+917.16%) | -2.04M (-4.67%) | -2.14M (+65.89%) | -1.29M (-43.17%) | -2.27M (-17.45%) | -2.75M (-2.83%) | -2.83M (-79.68%) | -13.93M (+380.34%) | -2.90M (-96.64%) | -86.33M (+1780.83%) | -4.59M | 1.47M | -990.00K (+98.00%) | -500.00K | - | - | - |
Ebit | -1.30M (+136.36%) | -550.00K (-97.35%) | -20.75M (+917.16%) | -2.04M (-4.67%) | -2.14M (+65.89%) | -1.29M (-43.17%) | -2.27M (-17.45%) | -2.75M (-2.83%) | -2.83M (-79.68%) | -13.93M (+380.34%) | -2.90M (-96.64%) | -86.33M (+1780.83%) | -4.59M | 1.47M | -990.00K (+98.00%) | -500.00K | - | - | - |
EBITDA | -1.79M (+163.24%) | -680.00K (-96.71%) | -20.66M (+834.84%) | -2.21M (-2.21%) | -2.26M (+96.52%) | -1.15M (-52.08%) | -2.40M (-12.73%) | -2.75M (-2.48%) | -2.82M (-79.76%) | -13.93M (+380.34%) | -2.90M (-96.64%) | -86.33M (+1780.83%) | -4.59M | 930K | -630.00K (+61.54%) | -390.00K | - | - | - |
Net Income | |||||||||||||||||||
Income Before Tax | - | -2.94M (-85.77%) | -20.66M (+834.84%) | -2.21M | - | -1.42M (-40.83%) | -2.40M (-12.73%) | -2.75M (-2.83%) | -2.83M (-79.68%) | -13.93M (+380.34%) | -2.90M (-96.64%) | -86.33M (+1780.83%) | -4.59M (+459.76%) | -820.00K | - | - | - | - | - |
Income Tax Expense | - | - | -850.00K | - | - | - | - | 10K | - | -600.00K | - | -7.81M (+643.81%) | -1.05M (+32.91%) | -790.00K | 50K | - | - | - | - |
Net Income From Continuing Operations | -1.79M (+163.24%) | -680.00K (-96.57%) | -19.81M (+796.38%) | -2.21M (-2.21%) | -2.26M (+59.15%) | -1.42M (-40.83%) | -2.40M (-13.04%) | -2.76M (-2.47%) | -2.83M (-78.79%) | -13.34M (+360.00%) | -2.90M (-96.31%) | -78.51M (+2117.80%) | -3.54M | 1.72M | -680.00K (+74.36%) | -390.00K | - | - | - |
Net Income | -1.79M (+163.24%) | -680.00K (-96.57%) | -19.81M (+796.38%) | -2.21M (-2.21%) | -2.26M (+59.15%) | -1.42M (-40.83%) | -2.40M (-13.04%) | -2.76M (-2.47%) | -2.83M (-78.79%) | -13.34M (+360.00%) | -2.90M (-96.31%) | -78.51M (+2117.80%) | -3.54M | 1.72M | -680.00K (+74.36%) | -390.00K | - | - | - |